A bipartisan coalition of 38 state Attorneys General have called on the FDA to take swift action against compounding pharmacies that "cut corners in pursuit of a quick profit" and sell knockoff drugs that could lead to "serious public health issues." The Ohio Attorney General recently issued a press release about letters it sent to 14 entities warning them to stop deceiving patients into believing that compounded drugs are approved by the FDA or have been reviewed for safety, effectiveness, or quality and declaring that patients "deserve clear and accurate information about the medication they're putting in their bodies." Similarly, in December 2024, the Illinois Attorney General issued cease-and-desist letters to five Chicagoland med spas advertising name brand medications like Wegovy and Ozempic but "instead offering unapproved versions of these products that may put people's health at risk." In addition, over a dozen Attorneys General have issued statements discussing the dangers posed by knockoff "semaglutide," including North Carolina, South Carolina, and Tennessee
Researchers running high-dose protocols that deplete vials quickly face less stability concern, but those on lower doses like 1mg or 2mg may find that a single vial lasts close to the stability window, making careful date tracking essential
(Source: biospectrumindia.com) April 2026: Eli Lilly and Company announced the U.S
Species that lacked either a GCG or GLP-1 sequence in the alignment were further removed to yield two final peptide sequence sets, each comprising 288 orthologous sequences
